Life Sciences Tools and Services
Company Overview of Knome, Inc.
Knome, Inc., a life sciences company, provides human genome interpretation software and services for academic, pharmaceutical, and biotech researchers in the United States and internationally. It offers tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. The company provides knomeCLINIC, a software suite that helps medical researchers and clinicians interpret human genomes for biological relevance; kGAP, a cloud-enabled genome informatics engine that automates the process of standardizing, distilling, annotating, and comparing sequence data; Desktop interpretation-support applications that allow medical re...
25 First Street
Cambridge, MA 02141
Founded in 2007
Key Executives for Knome, Inc.
Co-Founder and Chairman of Scientific Advisory Board
Co-Founder, Chief Strategy Officer and Director
Senior Vice President, General Counsel and Secretary
Compensation as of Fiscal Year 2015.
Knome, Inc. Key Developments
GENALICE and Knome Form Strategic Partnership to Empower Rapid NGS Data Interpretation
Jan 12 15
GENALICE and Knome, Inc. USA jointly announced a strategic partnership to offer their products together as a turn-key solution for those using next-generation sequencing (NGS) data to interpret patients’ genomes. genomes. GENALICE MAP is an ultra-fast and highly accurate preprocessing solution for aligning and calling NGS data and seamlessly connects to Knome’s informatics and genomics interpretation system, the knoSYS platform. While both products will continue to be offered separately, customers wanting to take advantage of the combined system can expect a reduction of NGS data bottlenecks, improved ability to annotate and interpret human genomes, and unprecedented control over their data from end-to-end.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries